Platelet Counts Compared for Thalassemia Patients
|
By LabMedica International staff writers Posted on 13 Jul 2017 |

Image: Clinical scientists analyzed the platelet counts of 249 patients with thalassemia, which were compared with the international reference method (IRM) for platelet counting in patients with thalassemia (Photo courtesy of Mahidol University).
Platelet count is the component of complete blood count that is used to diagnose quantitative defect in platelets. Accuracy of platelet count is essential for determining bleeding risk in patients and impedance platelet count is widely used in many clinical laboratories for routine patient testing.
A blood cell or particle fitting the platelet size profile of the platelet distribution curve is counted as a platelet. Although the quality of the impedance method has been continuously improved, inaccurate counting still occurs in many conditions. Abnormal red blood cells (RBCs) with low volume, including microcytes, schistocytes, and spherocytes, have been reported to be the cause of spuriously high platelet counts.
Clinical scientists at Mahidol University (Bangkok, Thailand) included in a study 249 patients with thalassemia who visited the outpatient hematology clinic at Siriraj Hospital, Bangkok, Thailand, during the March 2015 to August 2015. Peripheral blood specimens of study participants were collected in dipotassium ethylenediaminetetraacetic acid tubes and analyzed for platelet count by various methods within four hours after phlebotomy.
The fully automated Sysmex XN-3000 analyzer was used to measure platelet counts for the evaluated measurement methods in the study. To investigate the performance of automated platelet counts, including impedance (PLT-I) and optical fluorescent (PLT-O and PLT-F) methods, were compared with the international reference method (IRM) for platelet counting in patients with thalassemia. Red blood cell measurements were also analyzed on the Sysmex XN-300.
The team included specimens with platelet counts ranging from 31 × 103/μL to 932 × 103/μL and most of the patients were diagnosed with thalassemia major. Correlation between PLT-I and IRM was lower than that of the other methods in overall patients. PLT-O and PLT-F were correlated to IRM when classifying patients according to clinically significant platelet ranges. All automated methods had acceptable sensitivities; however, specificity of PLT-I was low for diagnosis of thrombocytopenia. High RDW-CV (red blood cell distribution width–coefficient of variation) was an independent factor of inaccurate PLT-I measurement.
The authors concluded that among the evaluated methods, PLT-I was the method least correlated to IRM, with PLT-O and PLT-F comparable to IRM in patients with thalassemia. Optical platelet counts and careful blood smear examination are recommended alternative platelet counting methods, depending on the clinical setting. The study was published in the June 2017 issue of the journal Archives of Pathology & Laboratory Medicine.
Related Links:
Mahidol University
A blood cell or particle fitting the platelet size profile of the platelet distribution curve is counted as a platelet. Although the quality of the impedance method has been continuously improved, inaccurate counting still occurs in many conditions. Abnormal red blood cells (RBCs) with low volume, including microcytes, schistocytes, and spherocytes, have been reported to be the cause of spuriously high platelet counts.
Clinical scientists at Mahidol University (Bangkok, Thailand) included in a study 249 patients with thalassemia who visited the outpatient hematology clinic at Siriraj Hospital, Bangkok, Thailand, during the March 2015 to August 2015. Peripheral blood specimens of study participants were collected in dipotassium ethylenediaminetetraacetic acid tubes and analyzed for platelet count by various methods within four hours after phlebotomy.
The fully automated Sysmex XN-3000 analyzer was used to measure platelet counts for the evaluated measurement methods in the study. To investigate the performance of automated platelet counts, including impedance (PLT-I) and optical fluorescent (PLT-O and PLT-F) methods, were compared with the international reference method (IRM) for platelet counting in patients with thalassemia. Red blood cell measurements were also analyzed on the Sysmex XN-300.
The team included specimens with platelet counts ranging from 31 × 103/μL to 932 × 103/μL and most of the patients were diagnosed with thalassemia major. Correlation between PLT-I and IRM was lower than that of the other methods in overall patients. PLT-O and PLT-F were correlated to IRM when classifying patients according to clinically significant platelet ranges. All automated methods had acceptable sensitivities; however, specificity of PLT-I was low for diagnosis of thrombocytopenia. High RDW-CV (red blood cell distribution width–coefficient of variation) was an independent factor of inaccurate PLT-I measurement.
The authors concluded that among the evaluated methods, PLT-I was the method least correlated to IRM, with PLT-O and PLT-F comparable to IRM in patients with thalassemia. Optical platelet counts and careful blood smear examination are recommended alternative platelet counting methods, depending on the clinical setting. The study was published in the June 2017 issue of the journal Archives of Pathology & Laboratory Medicine.
Related Links:
Mahidol University
Latest Hematology News
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
- Fast and Easy Test Could Revolutionize Blood Transfusions
- High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
- AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
- MRD Tests Could Predict Survival in Leukemia Patients
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
- ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
- First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes

- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







